Clinical Trials Sponsored by VDyne, Inc.

Total 35603 results

VDyne, Inc.

Recruiting

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US) (VISTA-US)

Tricuspid Regurgitation | Tricuspid Valve Disease | Tricuspid Valvular Disorders

United States
VDyne, Inc.

Recruiting

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation (VISTA)

Tricuspid Regurgitation | Tricuspid Valve Disease | Tricuspid Valvular Disorders

Australia, Czechia, Austria
Vyne Therapeutics Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Acne Vulgaris

United States
Vyne Therapeutics Inc.

Completed

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

Papulopustular Rosacea

United States
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

Psoriasis | Pruritus

United States
Vyne Therapeutics Inc.

Terminated

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Psoriasis | Pruritus | Atopic Dermatitis | Prurigo Nodularis

United States, Austria, Germany, Poland
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Pruritus

United States
Vyne Therapeutics Inc.

Completed

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Acne Vulgaris

United States
Vyne Therapeutics Inc.

Completed

Dermal Cumulative Irritant Patch Study

Healthy
Vyne Therapeutics Inc.

Completed

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy
Vyne Therapeutics Inc.

Completed

Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients

Acne Vulgaris

Israel
Vyne Therapeutics Inc.

Completed

VPD-737 for Treatment of Chronic Pruritus

Chronic Pruritus

United States
Vyne Therapeutics Inc.

Completed

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Acne Vulgaris

United States, Dominican Republic
Vyne Therapeutics Inc.

Completed

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Acne Vulgaris

United States, Dominican Republic
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Refractory Chronic Cough

United States, United Kingdom
Vyne Therapeutics Inc.

Terminated

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury (AUBURN)

Burns | Pruritus

United States
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Pruritus | Prurigo Nodularis

United States
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Vyne Therapeutics Inc.

Completed

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (EMIRA)

Rosacea | Papulopustular Rosacea

Germany
Vyne Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Australia
Vyne Therapeutics Inc.

Completed

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Prurigo Nodularis

Germany
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis (ATOMIK)

Pruritus | Atopic Dermatitis

United States
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Pruritus | Prurigo Nodularis

Austria, Germany, Poland
Vyne Therapeutics Inc.

Completed

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Overactive Bladder | Urinary Incontinence
Vyne Therapeutics Inc.

Completed

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Vyne Therapeutics Inc.

Completed

A Pharmacokinetic Study of Minocycline in Male and Female Volunteers

Acne

Israel
Vyne Therapeutics Inc.

Completed

Dermal Phototoxicity Study

Healthy
Vyne Therapeutics Inc.

Completed

Dermal Photo Allergic Skin Reaction

Healthy
Vyne Therapeutics Inc.

Completed

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Rash Due to Epidermal Growth Factor Receptor Inhibitors

Israel
Vyne Therapeutics Inc.

Terminated

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Rosacea

Israel
Vyne Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Impetigo

Israel
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping (DELIVER)

Duchenne Muscular Dystrophy (DMD)

United States, Belgium, Canada, United Kingdom, Australia, Spain, Italy
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 (ACHIEVE)

Myotonic Dystrophy Type 1 (DM1)

United Kingdom, France, Netherlands, Italy, Germany, New Zealand
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
M. Arkin 1999 Ltd.
Vyne Therapeutics Inc.

Completed

Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

Acne Vulgaris

Israel
Mylan Inc.
Vyne Therapeutics Inc.; DPT Laboratories, Ltd.

Completed

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

Scabies

United States, Dominican Republic, Honduras, Puerto Rico
Edward Lain, MD
Vyne Therapeutics Inc.

Completed

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
Jean Yuh Tang
Vyne Therapeutics Inc.; Epidermolysis Bullosa Research Partnership

Completed

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Pruritus | Epidermolysis Bullosa

United States
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
University of Kansas Medical Center
Hoffmann-La Roche; Seattle Children's Hospital; University of Rochester; University... and other collaborators

Recruiting

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) (MOVE FSHD)

FSHD

United States, Canada, United Kingdom
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
IGC Pharma LLC

Recruiting

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

Aggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive Outburst

United States, Canada, Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Recruiting

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States

3

Subscribe